Development and Validation of a Novel Prognostic Nomogram Based on Platelet and CD8⁺T Cell Counts in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Sun J, Guo R, Bi X, et al. Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in china (2021 edition). Liver Cancer. 2022;11(4):315–328. doi:10.1159/000523997
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Bekendam RH, Ravid K. Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms. Front Cell Dev Biol. 2023;11:1207395. doi:10.3389/fcell.2023.1207395
   PubMed Web of Science ®Google Scholar
• Zhang X, Yu S, Li X, et al. Research progress on the interaction between oxidative stress and platelets: another avenue for cancer? Pharmacol Res. 2023;191:106777. doi:10.1016/j.phrs.2023.106777
   PubMed Web of Science ®Google Scholar
• Patmore LA, Van Eekhout KMA, Buti M, et al. Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe. J Hepatol. 2023;S0168–S8278(23):05219.
   Google Scholar
• Morris K, Schnoor B, Papa AL. Platelet cancer cell interplay as a new therapeutic target. Biochim Biophys Acta BBA. 2022;1877(5):188770. doi:10.1016/j.bbcan.2022.188770
   PubMed Web of Science ®Google Scholar
• Zanetto A, Campello E, Pelizzaro F, et al. Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications. Liver Int. 2022;42(6):1229–1240. doi:10.1111/liv.15183
   PubMed Web of Science ®Google Scholar
• Ramadori P, Klag T, Malek NP, Heikenwalder M. Platelets in chronic liver disease, from bench to bedside. JHEP Rep. 2019;1(6):448–459. doi:10.1016/j.jhepr.2019.10.001
   PubMedGoogle Scholar
• Toubert C, Guiu B, Al Taweel B, et al. Prolonged survival after recurrence in HCC resected patients using repeated curative therapies: never give up! Cancers. 2022;15(1):232. doi:10.3390/cancers15010232
   PubMed Web of Science ®Google Scholar
• Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525–543. doi:10.1038/s41575-021-00438-0
   PubMed Web of Science ®Google Scholar
• Ferdous F, Scott T. The immunological capacity of thrombocytes. Int J Mol Sci. 2023;24(16):12950. doi:10.3390/ijms241612950
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng AL, Kokudo N, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–370. doi:10.1007/s12072-017-9799-9
   PubMed Web of Science ®Google Scholar
• Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161(6):1887–1895.e4. doi:10.1053/j.gastro.2021.08.050
   PubMed Web of Science ®Google Scholar
• Tay JK, Narasimhan B, Hastie T. Elastic net regularization paths for all generalized linear models. J Stat Softw. 2023;106(1). doi:10.18637/jss.v106.i01
   PubMed Web of Science ®Google Scholar
• Zhou XH, Li JR, Zheng TH, et al. Portal vein tumor thrombosis in hepatocellular carcinoma: molecular mechanism and therapy. Clin Exp Metastasis. 2023;40(1):5–32. doi:10.1007/s10585-022-10188-1
   PubMed Web of Science ®Google Scholar
• Cheng S, Hu G, Jin Z, Wang Z, Xue H. CT-based radiomics nomogram for prediction of survival after transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma and portal vein tumor thrombus. Eur Radiol. 2023;33(12):8715–8726. doi:10.1007/s00330-023-09830-7
   PubMed Web of Science ®Google Scholar
• Xu L, Wang P, Li L, et al. circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma. Mol Cancer. 2023;22(1):174. doi:10.1186/s12943-023-01882-z
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhang Z, Xu D, Yang X, Zhou L, Zhu Y. Identification and integrative analysis of ACLY and related gene panels associated with immune microenvironment reveal prognostic significance in hepatocellular carcinoma. Cancer Cell Int. 2021;21(1):409. doi:10.1186/s12935-021-02108-2
   PubMed Web of Science ®Google Scholar
• Jiang H, Qin Y, Wei H, et al. Prognostic MRI features to predict postresection survivals for very early to intermediate stage hepatocellular carcinoma. Eur Radiol. 2023;1:4.
   Google Scholar
• Pelizzaro F, Trevisani F, Simeon V, et al. Predictors of non‐transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection. Liver Int. 2023;43(12):2762–2775. doi:10.1111/liv.15719
   PubMed Web of Science ®Google Scholar
• Liu X, Hou Y, Wang X, et al. Machine learning-based development and validation of a scoring system for progression-free survival in liver cancer. Hepatol Int. 2020;14(4):567–576. doi:10.1007/s12072-020-10046-w
   PubMed Web of Science ®Google Scholar
• Norman JS, Li PJ, Kotwani P, Shui AM, Yao F, Mehta N. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. J Hepatol. 2023;79(6):1469–1477. doi:10.1016/j.jhep.2023.08.020
   PubMed Web of Science ®Google Scholar
• Kotwani P, Chan W, Yao F, Mehta N. DCP and AFP-L3 are complementary to AFP in predicting high-risk explant features: results of a prospective study. Clin Gastroenterol Hepatol. 2022;20(3):701–703.e2. doi:10.1016/j.cgh.2021.01.043
   PubMed Web of Science ®Google Scholar
• Liu X, Wang X, Yu L, et al. A novel prognostic score based on artificial intelligence in hepatocellular carcinoma: a long-term follow-up analysis. Front Oncol. 2022;12:817853. doi:10.3389/fonc.2022.817853
   PubMed Web of Science ®Google Scholar
• Xu W, Wang Y, Yang Z, Li J, Li R, Liu F. New Insights into a classification-based microvascular invasion prediction model in hepatocellular carcinoma: a multicenter study. Front Oncol. 2022;12:796311. doi:10.3389/fonc.2022.796311
   PubMed Web of Science ®Google Scholar
• Foerster F, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: safety and efficacy of current and emerging treatment options. J Hepatol. 2022;76(2):446–457. doi:10.1016/j.jhep.2021.09.007
   PubMed Web of Science ®Google Scholar
• Detopoulou P, Panoutsopoulos GI, Mantoglou M, et al. Relation of Mean Platelet Volume (MPV) with cancer: a systematic review with a focus on disease outcome on twelve types of cancer. Curr Oncol. 2023;30(3):3391–3420. doi:10.3390/curroncol30030258
   PubMed Web of Science ®Google Scholar
• Yin J, Niu Y, Qian L, Zhang X, Liu Z, Wang R. Mean platelet volume predicts survival in patients with hepatocellular carcinoma and type 2 diabetes. Diabet Res Clin Pract. 2019;151:120–127. doi:10.1016/j.diabres.2019.04.012
   PubMed Web of Science ®Google Scholar
• Zhang AB, Zhang ZH, Zhang J, et al. Lower mean platelet volume is a risk indicator of hepatocellular carcinoma recurrence following liver transplantation. Hepatobiliary Pancreat Dis Int. 2019;18(3):223–227. doi:10.1016/j.hbpd.2019.04.009
   PubMed Web of Science ®Google Scholar
• Scheiner B, Kirstein M, Popp S, et al. Association of platelet count and mean platelet volume with overall survival in patients with cirrhosis and unresectable hepatocellular carcinoma. Liver Cancer. 2019;8(3):203–217. doi:10.1159/000489833
   PubMed Web of Science ®Google Scholar
• Gallo P, Terracciani F, Di Pasquale G, Esposito M, Picardi A, Vespasiani-Gentilucci U. Thrombocytopenia in chronic liver disease: physiopathology and new therapeutic strategies before invasive procedures. World J Gastroenterol. 2022;28(30):4061–4074. doi:10.3748/wjg.v28.i30.4061
   PubMed Web of Science ®Google Scholar
• Lim J, Kim HI, Kim E, et al. Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study. BMC Cancer. 2021;21(1):11. doi:10.1186/s12885-020-07708-1
   PubMed Web of Science ®Google Scholar
• Yu L, Liu X, Wang X, et al. Impact of gender as a prognostic factor in HBV-related hepatocellular carcinoma: the survival strength of female patients in BCLC stage 0-B. J Cancer. 2019;10(18):4237–4244. doi:10.7150/jca.33430
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang K, Zhang X, et al. Thrombocytopenia: a prognostic factor for hepatocellular carcinoma patients with portal vein tumor thrombus after hepatectomy. J Gastroenterol Hepatol. 2019;34(7):1214–1221. doi:10.1111/jgh.14537
   PubMed Web of Science ®Google Scholar
• Li M, Dang Z, Ma S, et al. A novel prognostic scoring system to predict portal vein tumor thrombosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Am J Transl Res. 2023;15(7):4600–4609.
   PubMed Web of Science ®Google Scholar
• Chen KL, Gao J. Factors influencing the short-term and long-term survival of hepatocellular carcinoma patients with portal vein tumor thrombosis who underwent chemoembolization. World J Gastroenterol. 2021;27(13):1330–1340. doi:10.3748/wjg.v27.i13.1330
   PubMed Web of Science ®Google Scholar
• Li M, Zhao Y, Liu X, Zhang S, Jiang Y, Yang Z. Early risk warning system for distant metastasis of hepatitis B virus‑associated hepatocellular carcinoma with portal vein tumor thrombus. Oncol Lett. 2020;19(4):3249–3257. doi:10.3892/ol.2020.11423
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591–1601. doi:10.1016/S0140-6736(12)60209-8
   PubMed Web of Science ®Google Scholar
• Wenpei G, Yuan L, Liangbo L, et al. Predictive value of preoperative inflammatory indexes for postoperative early recurrence of hepatitis B-related hepatocellular carcinoma. Front Oncol. 2023;13:1142168. doi:10.3389/fonc.2023.1142168
   PubMed Web of Science ®Google Scholar
• Peng W, Li C, Zhang X, Wen T, Chen Z. The impact of thrombocytopenia on prognosis of HBV-related small hepatocellular carcinoma: a propensity score matching analysis. World J Surg Oncol. 2021;19(1):46. doi:10.1186/s12957-021-02160-2
   PubMed Web of Science ®Google Scholar
• Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: observational study. BMJ. 2018;362:k2817. doi:10.1136/bmj.k2817
   PubMed Web of Science ®Google Scholar
• Palumbo JS. Crosstalk between hemostasis and immunity in cancer pathogenesis. Thromb Res. 2022;213:S3–S7. doi:10.1016/j.thromres.2021.12.013
   PubMed Web of Science ®Google Scholar
• Zhang M, Ding Q, Bian C, Su J, Xin Y, Jiang X. Progress on the molecular mechanism of portal vein tumor thrombosis formation in hepatocellular carcinoma. Exp Cell Res. 2023;426(1):113563. doi:10.1016/j.yexcr.2023.113563
   PubMed Web of Science ®Google Scholar
• Joseph R, Soundararajan R, Vasaikar S, et al. CD8+ T cells inhibit metastasis and CXCL4 regulates its function. Br J Cancer. 2021;125(2):176–189. doi:10.1038/s41416-021-01338-5
   PubMed Web of Science ®Google Scholar
• Scherlinger M, Richez C, Tsokos GC, Boilard E, Blanco P. The role of platelets in immune-mediated inflammatory diseases. Nat Rev Immunol. 2023;23(8):495–510. doi:10.1038/s41577-023-00834-4
   PubMed Web of Science ®Google Scholar
• Koupenova M, Livada AC, Morrell CN. Platelet and megakaryocyte roles in innate and adaptive immunity. Circ Res. 2022;130(2):288–308. doi:10.1161/CIRCRESAHA.121.319821
   PubMed Web of Science ®Google Scholar
• Maouia A, Rebetz J, Kapur R, Semple JW. The immune nature of platelets revisited. Transfus Med Rev. 2020;34(4):209–220. doi:10.1016/j.tmrv.2020.09.005
   PubMed Web of Science ®Google Scholar
• Guo L, Shen S, Rowley JW, et al. Platelet MHC class I mediates CD8+ T-cell suppression during sepsis. Blood. 2021;138(5):401–416. doi:10.1182/blood.2020008958
   PubMed Web of Science ®Google Scholar
• Polasky C, Wendt F, Pries R, Wollenberg B. Platelet induced functional alteration of CD4+ and CD8+ T cells in HNSCC. Int J Mol Sci. 2020;21(20):7507. doi:10.3390/ijms21207507
   PubMed Web of Science ®Google Scholar